Peginesatide for Maintenance Treatment of Anemia in Hemodialysis and Nondialysis Patients Previously Treated with Darbepoetin Alfa | Zendy

Steven Fishbane | Zendy; Simon D. Roger | Zendy; Edouard Martin | Zendy; Grant Runyan | Zendy; Janet O’Neil | Zendy; Ping Qiu | Zendy; Francesco Locatelli | Zendy

Open Access

Peginesatide for Maintenance Treatment of Anemia in Hemodialysis and Nondialysis Patients Previously Treated with Darbepoetin Alfa

Author(s) -

Steven Fishbane,

Simon D. Roger,

Edouard Martin,

Grant Runyan,

Janet O’Neil,

Ping Qiu,

Francesco Locatelli

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03440412

Subject(s) - medicine , darbepoetin alfa , hemodialysis , anemia , dialysis , erythropoietin , hemoglobin , confidence interval , epoetin alfa , adverse effect , clinical endpoint , surgery , clinical trial

Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This study evaluated maintenance of hemoglobin levels in patients after conversion from darbepoetin alfa to once-monthly peginesatide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research